SPG21

Across TCGA pan-cancer cohorts, SPG21 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SPG21 data layer compared with 25 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher SPG21 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SPG21 expression acts as an unfavorable survival marker.

KIRC, READ, and BLCA are the cancer types where SPG21 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	OS	Median	All	0.122	0.811	<.001	30	view →
READ	DFS	Median	All	0.082	0.820	<.001	24	view →
BLCA	DFS	Median	IV	0.090	0.469	.009	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
COAD	DFS	Median	All	0.184	0.689	.039	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SPG21–KIRC (OS)

Open the KIRC breakdown →